Sichenzia Ross Friedman Ference LLP Advises Cell Source, Inc. on $500,000 PIPE Financing
New York, NY – April 1, 2015 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm represented Cell Source, Inc. (OTCQB: CLCS), a biomedical technology company focused on developing cell therapy treatments, on an offering pursuant to which Cell Source issued and sold two promissory notes in the aggregate amount of $500,000 and two Warrants to purchase common stock to two accredited investors.
The Sichenzia Ross Friedman Ference LLP team was led by Partner Gregory Sichenzia and Associate Jay Yamamoto.
- Sichenzia Ross Ference LLP Represents High Tide Inc. in the $8.0 million acquisition of Smoke Cartel, Inc. - January 25, 2021
- Sichenzia Ross Ference LLP Represents Genetic Technologies Limited in $6.56 Million Registered Direct Offering - January 25, 2021
- Sichenzia Ross Ference LLP Represents Document Security Systems, Inc. in $24 Million Upsized Public Offering of Common Stock - January 22, 2021